Currently, neutralizing TNF monoclonal antibodies have been widely accepted as one of the standard strategies for the treatment of severe steroid or immunomodulator-refractory or -dependent IBD patients (12), which results in remarkably improved rates of disease remission and mucosal healing (12). Here, TNF is linked to inflammatory bowel disease.